Clinical stage pharmaceutical company Lipella Pharmaceuticals has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its drug candidate, LP-310, which is intended to treat oral Graft-versus-Host Disease (GvHD).
Valneva Austria has received approval from the US Food and Drug Administration (FDA) for Ixchiq, the first chikungunya vaccine.
Mirati Therapeutics has received conditional marketing authorisation approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its advanced non-small cell lung cancer (NSCLC) therapy, Krazati (adagrasib).
Certa Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational therapy, FT011, to treat systemic sclerosis (scleroderma).
BeiGene has received a positive recommendation from the UK’s National Institute for Health and Care Excellence (NICE) for Brukinsa (zanubrutinib) to treat adults with chronic lymphocytic leukaemia (CLL).
Hyloris Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for new drug application (NDA) for Maxigesic IV to manage pain.
The National Medical Products Administration (NMPA) of China has accepted the new drug application (NDA) submitted by CANbridge Pharmaceuticals for CAN108 (Maralixibat Chloride Oral Solution/ LIVMARLI) for the treatment of cholestatic pruritus in patients aged two months and above with progressive familial intrahepatic cholestasis (PFIC).
Specialty pharmaceutical company Knight Therapeutics’s Brazilian affiliate, United Medical, has secured pricing approval for Minjuvi (tafasitamab) from the Drugs Market Regulation Chamber (CMED).
The US Food and Drug Administration (FDA) has granted clearance to Kyverna Therapeutics’ investigational new drug (IND) application enabling initiation of the Phase I/II KYSA-5 trial of KYV-101 to treat diffuse cutaneous systemic sclerosis (scleroderma).
The Taiwan Food and Drug Administration (TFDA) has granted marketing approval to CANbridge Pharmaceuticals’ CAN108 (Maralixibat Chloride Oral Solution/LIVMARLI) for the treatment of cholestatic pruritus in patients with alagille syndrome (ALGS), a rare genetic disorder.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.